Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…
tolebrutinib
Recommended Posts
- MRI marker cuts MS diagnosis time and avoids spinal taps, review finds
- Disrupted brain blood flow tied to poorer cognitive function in MS
- FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS
- More than 3 million people living with MS globally, report shows
- Learning to listen as I wage a never-ending, silent battle with chronic pain